GSK and Flagship Pioneering revealed the first company‑specific deals under their multi‑platform collaboration: Profound Therapeutics will apply its ProFoundry proteomics platform and Quotient Therapeutics will deploy somatic genomics to discover targets for COPD, IPF and metabolic dysfunction‑associated steatohepatitis. The initial pacts include upfront funding and options that could trigger substantial development and commercial milestones if GSK advances programs into clinical development. The arrangement validates venture‑built platform companies as de‑risking engines for large pharma and signals a sustained appetite for proteomic and genomic discovery engines in respiratory and liver disease.